Fexofenadine, an H1 receptor blocker, suppressed the expression of inflammatory cytokines, such as Il-6, IL-10, IL-4, and IL-17, and reduced infiltration of MDSCs into prostate tumors. This evidence concerns the gene IL6 and prostate neoplasm.